When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Prolactinoma

  • Обзор
  • Теория
  • Диагноз
  • Лечение
  • Последующее наблюдение
  • Источники
Последний просмотренный: 5 Jul 2026
Last updated: 22 Jul 2022

Резюме

Определение

Анамнез и осмотр

Ключевые диагностические факторы

  • presença de fatores de risco
  • amenorreia ou oligomenorreia
  • infertilidade
  • galactorreia
  • perda do desejo sexual (libido)
  • disfunção erétil
  • deterioração visual (por exemplo, hemianopsia temporal)
Полная информация

Другие диагностические факторы

  • osteoporose
  • oftalmoplegia
  • cefaleias
Полная информация

Факторы риска

  • predisposição genética (por exemplo, presença de mutação resultando em neoplasia endócrina múltipla-1 [NEM-1], adenoma hipofisário familiar isolado [FIPA])
  • terapia estrogênica
  • sexo masculino, de 30 a 60 anos de idade
  • sexo feminino, de 20 a 50 anos de idade
Полная информация

Диагностические исследования

Исследования, которые показаны в первую очередь

  • prolactina sérica
  • ressonância nuclear magnética (RNM) da hipófise
  • exame do campo visual computadorizado
Полная информация

Алгоритм лечения

ПРОДОЛЖЕНИЕ

mulheres na pré-menopausa

mulheres menopausadas

homens

Составители

Авторы

Niamh Martin, MB ChB, PhD, FRCP

Reader in Endocrinology

Imperial Centre for Endocrinology

Department of Metabolism, Digestion and Reproduction

Imperial College London

London

UK

Раскрытие информации

NM declares that she has no competing interests.

Выражение благодарностей

Dr Niamh Martin would like to gratefully acknowledge Dr Ilan Shimon, the previous contributor to this topic.

Раскрытие информации

IS receives consultancy and lecturing fees from Pfizer, Israel, and is an author of a number of references cited in this topic.

Рецензенты

Mark Molitch, MD

Professor

Division of Endocrinology

Northwestern University Feinberg School of Medicine

Chicago

IL

Раскрытие информации

MM is an author of a number of references cited in this topic.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Список литературы

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Основные статьи

Wildemberg LE, Fialho C, Gadelha MR. Prolactinomas. Presse Med. 2021 Dec;50(4):104080.Полный текст  Аннотация

Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88.Полный текст  Аннотация

Xia MY, Lou XH, Lin SJ, et al. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018 Jan;59(1):50-61. Аннотация

Статьи, указанные как источники

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Использование этого контента попадает под действие нашего заявления об отказе от ответственности